For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Quintiles to Increase Contract Sales Reps in Japan: Global Commercial Head Evangelista
February 26, 2014
- Shionogi Announces Reorganization to Boost R&D Capabilities
February 26, 2014
- Ranbaxy’s Toansa, Dewas Plants Voluntarily Suspend API Shipments Worldwide
February 26, 2014
- Takeda to Realign Japan Sales Team
February 25, 2014
- Ajinomoto Aims to Increase Operating Profit Rate to 10% in Pharmaceuticals Segment in FY2016 Under New Midterm Plan
February 24, 2014
- Multinational PIII Study of Revlimid for Follicular Lymphoma Starts in Japan: Celgene
February 24, 2014
- Sanofi to Begin Standalone Generic Operation in Japan
February 24, 2014
- Over 90% of Drug Makers Increasing Sales Rep Calls to Wholesalers Due to Imposed Restrictions
February 24, 2014
- ASKA Launches Leuplin Generic
February 21, 2014
- Diabetes Drug Sales Up 10% in 2013 Japan Market, Spurred by DPP-4 Inhibitors: IMS
February 21, 2014
- Plavix Tops Japan Ethical Drug Ranking, Sales Leap 14%: IMS
February 21, 2014
- US FDA Approves Droxidopa: DSP
February 20, 2014
- MTPC, Daiichi Sankyo Aim to Boost Sales of Struggling Tenelia
February 20, 2014
- RaQualia, Nagoya University Sign Industry-Academia Partnership Deal
February 20, 2014
- Future Relationship of Nichi-Iko and Sanofi in Question with Discontinuation of Biosimilar Codevelopment; Will They Continue to Work Together for Second AG?
February 20, 2014
- Astellas, AVEO Jettison Joint Development of Anticancer Agent Tivozanib
February 19, 2014
- Fujifilm Accepts Subscription Rights to J-TEC’s New Shares at 540 Million Yen, Commissioning Regenerative Medicine Products
February 19, 2014
- Eiken Chemical Taps Sales Division Head as New President
February 18, 2014
- US Biotech Acucela Makes Debut on TSE’s Mothers Market
February 18, 2014
- MTPC, JB to End Copromotion of Blood Plasma Products
February 18, 2014
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…